Marinomed Biotech Aktie 44956022 / ATMARINOMED6
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
06.10.2025 14:56:43
|
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
|
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Strategic Company Decision Ad hoc announcement Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Korneuburg, October 6, 2025 - Ad hoc announcement Following the successful recent capital measures, the Management Board of Marinomed Biotech AG, with the approval of the Supervisory Board, today decided to begin reviewing strategic options for the Marinosolv platform. Depending on the progress of the review, the evaluation process could include strategic partnerships for the two projects Budesolv and Tacrosolv, as well as the involvement of a strategist. Marinomed is working with an experienced consulting firm to support this process.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. End of Inside Information Information and Explanation of the Issuer to this announcement: Ad hoc announcement Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Korneuburg, October 6, 2025 - Ad hoc announcement Following the successful recent capital measures, the Management Board of Marinomed Biotech AG, with the approval of the Supervisory Board, today decided to begin reviewing strategic options for the Marinosolv platform. Depending on the progress of the review, the evaluation process could include strategic partnerships for the two projects Budesolv and Tacrosolv, as well as the involvement of a strategist. Marinomed is working with an experienced consulting firm to support this process.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.
06-Oct-2025 CET/CEST News transmitted by EQS Group. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 2208704 |
| End of Announcement | EQS News Service |
|
|
2208704 06-Oct-2025 CET/CEST
Nachrichten zu Marinomed Biotech AG
|
12:26 |
Schwacher Handel in Wien: ATX Prime schwächer (finanzen.ch) | |
|
09:28 |
Anleger in Wien halten sich zurück: ATX Prime zum Start des Donnerstagshandels im Minus (finanzen.ch) | |
|
15.10.25 |
Börse Wien: ATX Prime beendet die Mittwochssitzung in der Verlustzone (finanzen.ch) | |
|
15.10.25 |
Mittwochshandel in Wien: ATX Prime-Börsianer greifen am Nachmittag zu (finanzen.ch) | |
|
15.10.25 |
Aufschläge in Wien: ATX Prime am Mittag mit grünem Vorzeichen (finanzen.ch) | |
|
15.10.25 |
Optimismus in Wien: ATX Prime startet in der Gewinnzone (finanzen.ch) | |
|
14.10.25 |
Börse Wien: ATX Prime zum Handelsende in Rot (finanzen.ch) | |
|
14.10.25 |
Schwacher Handel in Wien: ATX Prime zeigt sich am Dienstagnachmittag schwächer (finanzen.ch) |
Analysen zu Marinomed Biotech AG
Gold auf Allzeithoch, Dollar unter Druck: Kippt jetzt der KI-Hype?
Gold auf Allzeithoch, US-Dollar unter Druck, KI-Hype, US-Schuldenkrise, Stagflation, Zinswende, Government Shutdown, steigende Anleiherenditen, Europa in der Zinsfalle (Frankreich, UK), Japan hebt Leitzinsen an, Immobilien- & Aktienblase in den USA, Notenbanken kaufen Gold.
Im Interview analysiert Marco Ludescher (Dr. Blumer & Partner Vermögensverwaltung Zürich) die Lage an den Kapitalmärkten. Olivia Hähnel (BX Swiss) hakt nach: Was bedeutet die Goldrally für Anleger? Kippt der KI-Hype? Wie wirken Schulden, Inflation und Zinspolitik auf Aktien, Anleihen und Immobilien?
Überblick:
– Gold & Währungen: Rekord-Gold vs. schwacher US-Dollar (DXY).
– Makro & Zinsen: Zinswende der Notenbanken vs. steigende Marktrenditen; Stagflations-Risiko.
– USA-Fokus: Defizite, Shutdown, Konsumdruck, Immobilienmarkt, Tech-Bewertungen.
– Europa: Frankreich & UK unter Druck; Emissionen, Hypotheken, Unternehmenslage.
– Japan: Ende der Ultra-Niedrigzinsen? YCC-Folgen für Yen & Renditen.
– KI & Tech: Investitionswelle (Nvidia, OpenAI, Oracle, CoreWeave, Meta, Amazon) – Chance oder KI-Blase?
– Takeaways: Rolle von Edelmetall-Produzenten, Diversifikation, schrittweises Vorgehen.
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Marinomed Biotech AG | 19.90 | 2.58% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Bilanzen von Nestlé und ABB im Fokus: SMI kräftig im Plus -- DAX stabil -- US-Börsen höher erwartet -- Asiens Börsen letztlich uneinheitlichDer heimische Aktienmarkt zeigt sich am Donnerstag mit Gewinnen. Der deutsche Aktienmarkt tendiert seitwärts. Die Wall Street dürfte am Donnerstag im Plus starten. An den Börsen in Asien waren letztlich verschiedene Vorzeichen zu sehen.